Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

PGE2-induced colon cancer growth is mediated by mTORC1.

Dufour M, Faes S, Dormond-Meuwly A, Demartines N, Dormond O.

Biochem Biophys Res Commun. 2014 Sep 5;451(4):587-91. doi: 10.1016/j.bbrc.2014.08.032. Epub 2014 Aug 13.

PMID:
25128827
2.

Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects.

Dufour M, Dormond-Meuwly A, Pythoud C, Demartines N, Dormond O.

Biochem Biophys Res Commun. 2013 Aug 16;438(1):32-7. doi: 10.1016/j.bbrc.2013.07.014. Epub 2013 Jul 15.

PMID:
23867821
3.

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.

Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, Dormond O.

BMC Cancer. 2012 Mar 8;12:86. doi: 10.1186/1471-2407-12-86.

4.

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.

Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O.

Mol Cancer. 2011 Jul 26;10:90. doi: 10.1186/1476-4598-10-90.

5.

The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.

Dormond-Meuwly A, Roulin D, Dufour M, Benoit M, Demartines N, Dormond O.

Biochem Biophys Res Commun. 2011 Apr 22;407(4):714-9. doi: 10.1016/j.bbrc.2011.03.086. Epub 2011 Mar 23.

PMID:
21439267
6.

Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of rapamycin in LS174T colon cancer cells.

Benoit M, Dormond-Meuwly A, Demartines N, Dormond O.

J Surg Res. 2011 May 15;167(2):e193-8. doi: 10.1016/j.jss.2011.01.015. Epub 2011 Feb 5.

PMID:
21324487
7.

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives.

Dufour M, Dormond-Meuwly A, Demartines N, Dormond O.

Cancers (Basel). 2011 May 24;3(2):2478-500. doi: 10.3390/cancers3022478.

8.

Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin.

Abdelnour-Berchtold E, Cerantola Y, Roulin D, Dormond-Meuwly A, Demartines N, Dormond O.

Anticancer Res. 2010 Mar;30(3):799-804.

PMID:
20392999
9.

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.

Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O.

Mol Cancer. 2010 Mar 12;9:57. doi: 10.1186/1476-4598-9-57.

Supplemental Content

Loading ...
Support Center